Related Experiment Video
Updated: Aug 6, 2026

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
Published on: July 6, 2017
The mighty mouse: genetically engineered mouse models in cancer drug development
Norman E Sharpless1, Ronald A Depinho
1Departments of Medicine and Genetics, The Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, North Carolina 27599-7295, USA. nes@med.unc.edu
Abstract:
Deficiencies in the standard preclinical methods for evaluating potential anticancer drugs,such as xenograft mouse models, have been highlighted as a key obstacle in the translation of the major advances in basic cancer research into meaningful clinical benefits. In this article, we discuss the established uses and limitations of xenograft mouse models for cancer drug development, and then describe the opportunities and challenges in the application of novel genetically engineered mouse models that more faithfully mimic the genetic and biological evolution of human cancers. Greater use of such models in target validation, assessment of tumour response, investigation of pharmacodynamic markers of drug action, modelling resistance and understanding toxicity has the potential to markedly improve the success of cancer drug development.
Insights
Standard preclinical cancer drug testing models like xenografts have limitations. Novel genetically engineered mouse models offer better human cancer mimicry, potentially improving drug development success rates and clinical translation.
Area of Science:
- Oncology
- Translational Medicine
- Preclinical Drug Development
Background:
- Standard preclinical models, such as xenograft mouse models, face significant limitations in accurately predicting human cancer drug efficacy.
- These limitations hinder the translation of basic cancer research discoveries into effective clinical treatments.
Purpose of the Study:
- To discuss the established uses and limitations of xenograft mouse models in cancer drug development.
- To explore the potential of novel genetically engineered mouse models (GEMMs) that better recapitulate human cancer evolution.
- To identify opportunities and challenges in applying GEMMs for improved cancer drug discovery.
Main Methods:
- Review of existing literature on xenograft models for cancer drug evaluation.
- Description of the characteristics and advantages of genetically engineered mouse models.
- Analysis of the application of GEMMs in key stages of drug development.
Main Results:
- Xenograft models have inherent limitations in mimicking human cancer's genetic and biological complexity.
- Genetically engineered mouse models offer a more faithful representation of human cancer progression and heterogeneity.
- GEMMs show promise in target validation, response assessment, pharmacodynamic studies, resistance modeling, and toxicity evaluation.
Conclusions:
- Greater utilization of genetically engineered mouse models can significantly enhance the success rate of anticancer drug development.
- Addressing the challenges associated with GEMMs is crucial for their widespread adoption.
- Improved preclinical models are essential for bridging the gap between basic research and clinical benefit in oncology.
Related Concept Videos
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
In-vitro Mutagenesis

